Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 10/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 10/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17469512 | 0.89 | PRMT5 (0.37) | CARM1PRMT1PRMT5WDR77SLC6A4 | |
| SCHEMBL17469469 | 0.89 | PRMT5 (0.37) | CARM1PRMT1PRMT5WDR77ABL1 | |
| SCHEMBL16120045 | 0.86 | TTK (0.39) | CARM1PRMT1 | |
| SCHEMBL17469496 | 0.86 | PRMT1 (0.39) | CARM1PRMT1LRRK2 | |
| SCHEMBL17469497 | 0.85 | PRMT1 (0.38) | CARM1PRMT1PRMT5WDR77SLC6A4 | |
| SCHEMBL17469483 | 0.85 | PRMT1 (0.35) | CARM1PRMT1LRRK2 | |
| SCHEMBL16119992 | 0.85 | FADS1 (0.41) | CARM1PRMT1PRMT5WDR77SLC6A4 | |
| SCHEMBL17469449 | 0.82 | PRMT1 (0.37) | CARM1PRMT1PRMT5WDR77HTR2A | |
| SCHEMBL17469509 | 0.82 | PRMT1 (0.43) | PRMT1PRMT5WDR77SLC6A2HTR2A | |
| SCHEMBL17469504 | 0.82 | HTR2A (0.44) | PRMT1SLC6A4SLC6A2HTR2ALRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105497-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2018-04-19 | — | — | US | disclosed |
| US-9765035-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160024017-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024017-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | CARM1 12/4885PRMT1 1/4885PRMT5 3/4885 |
| US-20180105497-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | CARM1 12/4885PRMT1 1/4885PRMT5 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.